cardiovascular prevention - antiplatelets drug - primary prevention clinical trials results meta-analysis

<h1> <a href="TM4-2-antiplatelets drug-cardiovascular prevention" > <strong>cardiovascular prevention</strong> - antiplatelets drug </a> - primary prevention trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="../TRC_t4257.htm"> British Doctor’s Trial, 1988 </a> <br> </td> <td> aspirin 500 mg/d<br>  <i>versus</i> <br> no aspirin </td> <td> Healthy men </td> <td> follow-up <br> n=3429/1710<br> Parallel groups<br> open <br> UK </td> </tr> <tr> <td> <a href="../TRC_t4258.htm"> Physicians Health Study, 1989 </a> <br> NCT00000500 </td> <td> aspirin 325 mg every other day<br>  <i>versus</i> <br> placebo </td> <td> Healthy men </td> <td> follow-up 60.2 months<br> n=11037/11034<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="../TRC_t4259.htm"> Thrombosis Prevention Trial, 1998 </a> <br> NCT00000614 </td> <td> aspirin 75 mg/d (controlled release)<br>  <i>versus</i> <br> placebo </td> <td> Men at high risk of CHD </td> <td> follow-up median 6.8y<br> n=2545/2540<br> Factorial plan<br> double blind <br> UK </td> </tr> <tr> <td> <a href="../TRC_t4260.htm"> HOT, 1998 </a> <br> </td> <td> aspirin 75 mg daily<br>  <i>versus</i> <br> placebo </td> <td> patients aged 50-80 with hypertension and diastolic blood pressure between 100 mmHG and 115 mmHG </td> <td> follow-up mean 3.8 y (range 3.3-4.9y)<br> n=9399/9391<br> Factorial plan<br> Double blind <br> Europe, North and South America, and Asia </td> </tr> <tr> <td> <a href="../TRC_t4261.htm"> Primary Prevention Project, 2001 </a> <br> </td> <td> aspirin 100 mg/d<br>  <i>versus</i> <br> no aspirin (open control) </td> <td> men and women aged 50 years or greater, with at least one of the major recognised cardiovascular risk factors. </td> <td> follow-up 3.6 y<br> n=2226/2269<br> Factorial plan<br> Open <br> </td> </tr> <tr> <td> <a href="../TRC_t4691.htm"> Women’s Health Study, 2005 </a> <br> </td> <td> aspirin 100mg daily<br>  <i>versus</i> <br> placebo </td> <td> initially healthy women 45 years of age or older </td> <td> follow-up 10.1 y mean (range 8.2 to 10.9<br> n=19934/19942<br> Factorial plan<br> Double blind <br> </td> </tr> <tr> <td> <a href="../TRC_t9895.htm"> AAA, 2009 </a> <br> </td> <td> 100mg enteric coated aspirin<br>  <i>versus</i> <br> placebo </td> <td> men and women aged 50 to 80 years with asymptomatic atherosclerosis detected by low ankle brachial index (<=0.95) </td> <td> follow-up 8.2 y (mean)<br> n=1675/1675<br> Parallel groups<br> double blind <br> UK </td> </tr> </table> <h2>References</h2> <p> <b>British Doctor’s Trial, 1988 : </b> Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton SRandomised trial of prophylactic daily aspirin in British male doctors. <i>Br Med J (Clin Res Ed) 1988 Jan 30;296:313-6</i> [PMID 3125882] </p> <p> <b>Physicians Health Study, 1989 : </b> Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. <i>N Engl J Med 1989 Jul 20;321:129-35</i> [PMID 2664509] </p> <p> <b>Thrombosis Prevention Trial, 1998 : </b> Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. <i>Lancet 1998 Jan 24;351:233-41</i> [PMID 9457092] </p> <p> <b>HOT, 1998 : </b> Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling SEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. <i>Lancet 1998 Jun 13;351:1755-62</i> [PMID 9635947] </p> <p> <b>Primary Prevention Project, 2001 : </b> de Gaetano GLow-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. <i>Lancet 2001 Jan 13;357:89-95</i> [PMID 11197445] </p> <p> <b>Women’s Health Study, 2005 : </b> Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JEA randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. <i>N Engl J Med 2005 Mar 31;352:1293-304</i> [PMID 15753114] </p> <p> <b>JPAD DOUBLON à effacer, 2008 : </b> Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito YLow-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. <i>JAMA 2008;300:2134-41</i> [PMID 18997198] </p>